Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized recovery trial
Purpose Evaluate the impact of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) on
retinal nonperfusion (RNP) in eyes with proliferative diabetic retinopathy (PDR). Design
Prospective, randomized clinical trial. Participants Eyes with treatment-naïve PDR and
extensive RNP without diabetic macular edema. Methods Patients were randomized 1: 1 to
intravitreal 2 mg aflibercept every 4 weeks (monthly) or every 12 weeks (quarterly). Main
Outcome Measures The primary outcome measure was change in total RNP area (in square …
retinal nonperfusion (RNP) in eyes with proliferative diabetic retinopathy (PDR). Design
Prospective, randomized clinical trial. Participants Eyes with treatment-naïve PDR and
extensive RNP without diabetic macular edema. Methods Patients were randomized 1: 1 to
intravitreal 2 mg aflibercept every 4 weeks (monthly) or every 12 weeks (quarterly). Main
Outcome Measures The primary outcome measure was change in total RNP area (in square …
以上显示的是最相近的搜索结果。 查看全部搜索结果